Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC1A3 | P43003 | 1/20 | 0.48 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.48 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.43 |
| ▸ | GRIA2 | P42262 | 2/20 | 0.43 |
| ▸ | GRIA4 | P48058 | 2/20 | 0.43 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.43 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.43 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.43 |
| ▸ | GRIK2 | Q13002 | 1/20 | 0.43 |
| ▸ | GLUL | P15104 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9003529 | 1.00 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| SCHEMBL9003541 | 1.00 | SLC1A3 (0.48) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| SCHEMBL9003813 | 0.78 | CYP2D6 (0.44) | — | |
| SCHEMBL9003822 | 0.78 | CYP2D6 (0.44) | — | |
| SCHEMBL10212363 | 0.76 | SLC7A5 (0.58) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| SCHEMBL21585639 | 0.76 | SLC7A5 (0.58) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| SCHEMBL21690060 | 0.76 | SLC7A5 (0.58) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| SCHEMBL21577845 | 0.76 | SLC7A5 (0.58) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| SCHEMBL434919 | 0.76 | SLC7A5 (0.58) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 | |
| SCHEMBL434918 | 0.76 | SLC7A5 (0.58) | SLC1A3SLC1A2SLC1A1SLC7A5GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2025-09-18 | — | — | US | disclosed |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | PARIS SCIENCES ET LETTRES (FR) | 2025-06-03 | — | — | US | disclosed |
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2020-05-28 | — | — | US | disclosed |
| EP-3651758-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | Paris Sciences et Lettres - Quartier Latin (FR) | 2020-05-20 | — | — | EP | disclosed |
| WO-2019012109-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | PARIS SCIENCES ET LETTRES - QUARTIER LATIN (FR) | 2019-01-17 | — | — | WO | disclosed |
| US-5538958-A | NMDA antagonists | MERRELL PHARMACEUTICALS INC. (US) | 1996-07-23 | — | — | US | disclosed |
| US-5500419-A | NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1996-03-19 | — | — | US | disclosed |
| CN-1027694-C | Process for preparing N-methyl-D-aspartic acid antagonist | MERRELL DOW PHARMA (US) | 1995-02-22 | — | — | CN | disclosed |
| EP-0418863-B1 | NMDA antagonists | MERRELL DOW PHARMA (US) | 1995-01-04 | — | — | EP | disclosed |
| US-5326756-A | R-4-oxo-5 phosphononorvaline used as NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-07-05 | — | — | US | disclosed |
| US-5095009-A | NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1992-03-10 | — | — | US | disclosed |
| CN-1050387-A | The N-methyl-D-aspartate antagonist | MERRELL DOW PHARMA (US) | 1991-04-03 | — | — | CN | disclosed |
| EP-0418863-A2 | NMDA antagonists | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200163916-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | SLC1A3 36/4885SLC1A2 3/4885SLC1A1 18/4885 |
| US-20250288544-A1 | PROBENECID FOR USE IN TREATING EPILEPTIC DISEASES, DISORDERS OR CONDITIONS | NLN, CLN6, SLC1A2 | SLC1A3 36/4885SLC1A2 3/4885SLC1A1 18/4885 |
| US-12318358-B2 | Probenecid for use in treating epileptic diseases, disorders or conditions | NLN, CLN6, SLC1A2 | SLC1A3 36/4885SLC1A2 3/4885SLC1A1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.